SLP vs TMO
SLP: Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | SLP | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $18.33 | $559.53 | |
| Market cap as of 2026-08-02 | $371M | $206.9B | |
| P/E as of 2026-08-02 | 45.49 | 30.64 | TMO lower |
| PEG as of 2026-08-02 | n/a | 3.39 | |
| Net margin as of 2026-08-02 | +9.9% | +15.0% | TMO higher |
| Gross margin as of 2026-08-02 | +63.4% | +40.9% | SLP higher |
| Operating margin as of 2026-08-02 | +14.0% | +17.6% | TMO higher |
| ROE as of 2026-08-02 | +6.2% | +13.3% | TMO higher |
| ROA as of 2026-08-02 | +5.7% | +6.3% | TMO higher |
| Debt / equity as of 2026-08-02 | 0.00 | 0.81 | SLP lower |
| Revenue growth (YoY) as of 2026-08-02 | +2.1% | +7.2% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | +13.7% | -0.3% | SLP higher |
| Dividend yield as of 2026-08-02 | +0.6% | +0.3% | SLP higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-02 | 1.34 | 0.85 | |
| 1-year return as of 2026-07-27 close | +38.5% | +17.0% | SLP higher |
Fundamentals: market data, as of 2026-08-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.